Core Insights - BioGrowing showcased its innovative Akkermansia muciniphila Double Star portfolio at SupplySide Global 2025, marking a significant advancement in microbiome science and metabolic health solutions [1] Product Innovations - The AKK WST01 live strain is the first RCT-validated AKK strain in China, showing significant improvements in blood sugar control and weight management, with studies published in Cell Metabolism [3] - The AKKBG-001™ inactivated strain utilizes proprietary fermentation technology to produce high-purity bacterial powder, ensuring safety and quality [4] - The AKKBG-001™ weight management product contains 30 billion TFU of probiotic powder combined with EGCG green tea extract and vitamins B and C, enhancing its effectiveness for consumers [6] Market Opportunities - The Flora-Focus® series addresses nine health scenarios, including gut health, immunity, and female care, demonstrating strong customization capabilities to meet diverse client needs [8] - The global vaginal health probiotic supplements market is projected to grow from US$665.12 million in 2024 to US$1,195.08 million by 2032, with a CAGR of 7.6%, highlighting the potential in the female care segment [9] New Product Launches - BioGrowing introduced the OralBubble™ Probiotic Microbubble Lozenge, which features a unique microbubble disintegration technology, delivering 10 billion CFU of active bacteria without the need for water [11] Production and Quality Standards - As Asia's largest probiotic production base, BioGrowing has an annual capacity of 1,200 tons and adheres to the "Six-Diamond" quality standard, ensuring compliance with various international certifications [12] Strategic Vision - The company emphasizes a holistic approach, providing clinically backed, scalable solutions to meet evolving consumer demands across multiple health categories [13] - BioGrowing aims to translate cutting-edge research into effective health solutions through global partnerships, contributing to sustainable industry progress [15]